Study on the Relationship Between FcγRⅢa 158V/F Polymorphism and the Efficacy of Rituximab-Based Regimens in the First-Line Treatment of Diffuse Large B Cell Lymphoma

JIN Xuan,DENG Lijuan,WANG Xiaogan,DING Ning,SONG Yuqin,ZHU Jun

DOI: https://doi.org/10.3969/j.issn.1009-0460.2017.05.005

2017-01-01

Chinese Clinical Oncology

Abstract:Objective To explore the relationship between Fc gamma receptor Ⅲa 158V/F (FcγRⅢa 158V/F) polymorphism and clinical response to standard frontline treatment with rituximab (RTX)-based regimens in Chinese diffuse large B-cell lymphoma (DLBCL) patients.Methods Nested PCR combined with sanger sequencing were used to detected FcγRⅢa 158V/F genotypes in 265 DLBCL patients.All patients receiving 6 (1-8) cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) as frontline therapy were assessable for the efficacy.The relationship between FcγRⅢa 158V/F polymorphism and the efficacy and prognosis of patients was analyzed.Results Among 265 patients, 27 (10.2%) patients with V/V genotype, 107 (40.4%) with V/F and 131 (49.4%)with F/F were identified.Patients with different FcγRⅢa 158V/F genotypes did not have any difference in terms of age, molecular subtypes, lactate dehydrogenase (LDH) or international prognostic index (IPI);However, it only related to gender(P<0.05).The overall response rate (RR) was 85.2%, 84.1% and 83.2% in V/V, V/F and F/F, respectively.There was no significant difference between the treatment responses of the three groups (P>0.05).With a median follow-up of 60.7 months(range: 0.8-109.5), 103(38.9%)patients relapsed or progressed, and 77(29.1%) died.There was no difference between homozygous F/F and V allele carriers as for the 5-year progression-free survival rate (61.1% vs.62.4%, P=0.757) and 5-year overall survival rate (69.2% vs.74.2%, P=0.278).But in the subgroup of early stage (Ⅰ-Ⅱ), patients with V allele carriers were found to have a higher 5-year overall survival rate than that in homozygous F (94.7% vs.77.3%, P=0.003).The 5-year progression-free survival rates for F/F genotype and V/V+V/F genotype were 85.9% and 75.9% (P>0.05).As for Ⅲ-Ⅳ stage, there was no significant difference in progression-free survival rate and overall-survival rate between patients with different FcγRⅢa 158V/F genotypes (P>0.05).Conclusion FcγRⅢa 158V/F polymorphisms could not predict response to RTX-based regimes as frontline therapy for DLBCL patients, but in the subgroup of early stage, this polymorphism may be a biomarker to predict response.